- Title
- Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study
- Creator
- Ito, Tomoki; Sanford, David; Guvenc, Birol; Bui, Cat N.; Delgado, Alex; Duan, Yinghui; Guijarro, Belen Garbayo; Llamas, Cynthia; Lee, Je-Hwan; Tomuleasa, Ciprian; Hsiao, Hui-Hua; Olivera, Leonardo José Enciso; Enjeti, Anoop Kumar; Conca, Alberto Gimenez; Del Castillo, Teresa Bernal; Girshova, Larisa; Martelli, Maria Paola
- Relation
- European Journal of Haematology Vol. 109, Issue 1, p. 58-68
- Publisher Link
- http://dx.doi.org/10.1111/ejh.13769
- Publisher
- Wiley-Blackwell
- Resource Type
- journal article
- Date
- 2022
- Description
- Objectives: This retrospective chart review examined real- world healthcare resource utilization (HRU) in patients with AML ineligible for intensive therapy who received first-line systemic therapy or best supportive care (BSC). Methods: Data were collected anonymously on patients with AML who initiated first-line hypomethylating agents (HMA), low-dose cytarabine (LDAC), other systemic therapy, or BSC. HRU endpoints included hospitalizations, outpatient consultations, transfusions, and supportive care. Results: Of 1762 patients included, 46% received HMA, 11% received LDAC, 17% received other systemic therapy, 26% received BSC; median treatment durations were 118, 35, 33, and 57 days, respectively. Most patients were hospitalized, most commonly for treatment administration, transfusion, or infection (HMA 82%, LDAC 93%, other systemic therapy 83%, BSC 83%). A median number of hospitalizations were 2–6 across systemic groups and two for BSC, with median durations of 8–18 days. Transfusion rates and outpatient consultations were highest for HMA (80% and 79%) versus LDAC (57% and 53%), other systemic therapy (57% and 63%), and BSC (71% and 66%). Antivirals/antibiotics and antifungals were used more frequently than growth factors (72–92%, 34–63%, and 7–27%, respectively). Conclusion: Patients with AML ineligible for intensive therapy have high HRU; novel therapies are needed to alleviate this burden.
- Subject
- AML; best supportive care,; healthcare resource utilization; hypomethylating agents; low-dose cytarabine; low-intensity therapy; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1489886
- Identifier
- uon:52804
- Identifier
- ISSN:0902-4441
- Rights
- © 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- Language
- eng
- Full Text
- Reviewed
- Hits: 1604
- Visitors: 1636
- Downloads: 61
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 586 KB | Adobe Acrobat PDF | View Details Download |